drugset / Trial / NCT01381731

A Double-masked, Randomized, Placebo-controlled,Pilot Study of Diquafosol Tetrasodium in Subjects Following Photorefractive Keratectomy (PRK)

NCT01381731

Phase 2 Terminated 14 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objectives of this trial are to: * Assess the safety and tolerability of diquafosol tetrasodium ophthalmic solution versus placebo following one week of treatment in subjects undergoing photorefractive keratectomy (PRK). * Evaluate the potential of diquafosol to accelerate corneal wound healing/re-epithelialization following PRK.

Timeline

Start
2005-04
Primary completion
2005-06
Completion
2005-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Diquafosol Oligonucleotide (other) 2 % Topical

Indications

No indication recorded.